Centessa Pharmaceuticals (Centessa Pharmaceuticals) FCF Margin % : -453.49% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Centessa Pharmaceuticals's Free Cash Flow for the three months ended in Dec. 2023 was $-31.08 Mil. Centessa Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $6.85 Mil. Therefore, Centessa Pharmaceuticals's FCF Margin % for the quarter that ended in Dec. 2023 was -453.49%.

As of today, Centessa Pharmaceuticals's current FCF Yield % is -15.13%.

The historical rank and industry rank for Centessa Pharmaceuticals's FCF Margin % or its related term are showing as below:

CNTA' s FCF Margin % Range Over the Past 10 Years
Min: -2342.2 Med: -2342.2 Max: -2342.2
Current: -2342.2

During the past 5 years, the highest FCF Margin % of Centessa Pharmaceuticals was -2342.20%. The lowest was -2342.20%. And the median was -2342.20%.

CNTA's FCF Margin % is ranked worse than
83% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs CNTA: -2342.20

Centessa Pharmaceuticals FCF Margin % Historical Data

The historical data trend for Centessa Pharmaceuticals's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals FCF Margin % Chart

Centessa Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-2,342.20

Centessa Pharmaceuticals Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial									-	-	-	-	-453.49

Competitive Comparison of Centessa Pharmaceuticals's FCF Margin %

For the Biotechnology subindustry, Centessa Pharmaceuticals's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Centessa Pharmaceuticals's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's FCF Margin % falls into.

Centessa Pharmaceuticals FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Centessa Pharmaceuticals's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-160.511	/	6.853
	=	-2,342.20 %

Centessa Pharmaceuticals's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-31.078	/	6.853
	=	-453.49 %

Centessa Pharmaceuticals FCF Margin % Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

260:Germany

Address

1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT

Website

https://www.centessa.com

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Executives

Harris Rotman	officer: SVP Regulatory Affairs	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Tia L Bush	officer: Chief Quality Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson	officer: Chief People Officer	C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
David J Grainger	officer: Chief Innovation Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Gregory M Weinhoff	officer: Chief Financial Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman	officer: Chief Technology Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David M Chao	officer: Chief Administrative Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain	officer: General Counsel	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Mathias Hukkelhoven	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha	director, officer: Chief Executive Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi	officer: Chief Medical Officer	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd	10 percent owner	C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De	director	C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff	director	C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH